Gilead Sciences Chairman and Chief Executive Daniel Patrick O’Day reported a significant personal securities transaction on February 5, 2026. According to a Form 4 filed with the Securities and Exchange Commission, O’Day sold 115,640 shares of Gilead common stock at $150.00 per share, generating proceeds of $17,346,000.
The filing shows the sale was paired with an option exercise. O’Day exercised options to acquire 115,640 shares at an exercise price of $66.01, giving the exercised position a total value of $7,633,396. Both the sale and the exercise were executed under a pre-arranged Rule 10b5-1 trading plan that O’Day adopted on February 28, 2025, the Form 4 indicates.
After completing the share sale, O’Day is listed as directly owning 613,912 shares of Gilead common stock. The Form 4 provides the formal record of these transactions and their mechanics but does not include commentary on the executive’s rationale beyond the use of the predetermined 10b5-1 plan.
In related company developments, Gilead has recorded several notable items affecting product and commercial outlooks. The U.S. Food and Drug Administration has removed earlier restrictions on Yescarta, a CAR T-cell therapy, for patients with relapsed or refractory primary central nervous system lymphoma. That regulatory change expands available treatment options for this rare, aggressive subset of non-Hodgkin lymphoma.
Analyst activity around Gilead has shifted upward in recent coverage. Leerink Partners raised its price target for Gilead to $146, citing strong commercial uptake of Yeztugo, which is referenced as an important element of Gilead’s HIV pipeline. Truist Securities increased its price target to $145 while maintaining a Buy rating, pointing to Gilead’s leading position in the HIV market. BMO Capital also lifted its target to $150, attributing the move to momentum in Gilead’s HIV business and substantial sales tied to the Yeztugo launch.
Collectively, the insider transaction, the FDA action on a CAR T product, and the cluster of analyst upgrades illustrate concurrent governance, regulatory and commercial developments at Gilead. The Form 4 documents the mechanics of the CEO’s sale and option exercise and the company announcements and analyst notes outline recent product-level and market assessments that market participants may consider.